Phenotype, function and T cell receptor repertoire of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma by unknown
POSTER PRESENTATION Open Access
Phenotype, function and T cell receptor
repertoire of tumor-infiltrating lymphocytes in
patients with pancreatic ductal adenocarcinoma
Isabel Poschke1*, Michael Flossdorf1, Marta Faryna2, Frank Bergmann3, Jessica Hassel3, Oliver Strobel1,
Rienk Offringa1
From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
National Harbor, MD, USA. 4-8 November 2015
Background
Pancreatic ductal adenocarcinoma (PDAC) is a devastat-
ing disease with a median survival of only about two
years even in the 20% of patients that present early
enough to be eligible for surgical resection and adjuvant
chemotherapy. With this urgent medical need in mind,
we are exploring the use of adoptive T cell transfer in
patients with PDAC, as this therapy has shown remark-
able clinical success in patients with advanced melanoma.
Results
Despite the notion that, different from melanoma,
PDAC is a non-immunogenic tumor, we observe at least
moderate (>150 CD3+cells/mm2) T cell infiltration in
60% of patient biopsies analyzed by immunohistochem-
istry (n=66). Flow cytometric analysis shows that tumor-
infiltrating T lymphocytes (TILs) predominantly display
an activated effector memory phenotype with signs of
exhaustion or prolonged antigen exposure, such as high
PD1 (n≥30).
Upon in vitro culture TILs can be expanded from 85%
of PDAC patients (n=96) and show growth capacity and
phenotypes similar to melanoma patient TIL (n=62).
The majority of tested PDAC TIL cultures produce
IFN-g in response to autologous tumor cells in an
MHC-I dependent manner, but cross-reactivity and a
low response magnitude are common observations.
In order to gain insight into the original tumor-reac-
tivity of TILs before expansion, we studied the T cell
receptor (TCR) repertoire by deep sequencing and made
the following observations: the TIL TCR repertoire is
i) distinct from the broad repertoire observed in the
blood; ii) usually dominated by large T cell clones, pos-
sibly due to in situ expansion after tumor-antigen
encounter; and iii) in most patients not maintained dur-
ing the TIL expansion period, likely leading to a loss of
important T cell clones and a shift in tumor-reactivity
in the TILs available for patient treatment after in vitro
expansion.
Deep sequencing of the TCR repertoire in combina-
tion with TCR cloning provides us with a tool to study
TIL reactivity directly ex vivo and to ‘rescue’ TIL-TCRs
with valuable reactivities that could be reintroduced in
the form of genetically engineered T cells. Whether
PDAC TILs are reactive towards shared antigens and/or
mutation-derived neo-antigens is currently being investi-
gated based on exome and RNA sequencing data from a
subset of patients.
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